Royston Ivor's Form 4 filing
Viracta Therapeutics, Inc.VIRX · filed Nov 29, 2021
- Accession no.
- 0001209191-21-067044
- Filed
- Nov 29, 2021, 7:46 PM ET
- Trade date
- Nov 25-29, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $133.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Royston IvorCIK 0001026765 | Director, Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2021 | Common Stock | MOption exerciseAcquired | +50,437 | $0.00F1 | $0 | 599,036 | Direct | |
| Nov 26, 2021 | Common Stock | SSaleDisposed | −11,914 | $4.80F3 | −$57,194.35 | 587,122 | Direct | |
| Nov 29, 2021 | Common Stock | SSaleDisposed | −15,833 | $4.82F4 | −$76,300.81 | 571,289 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2021 | Common Stock | MOption exerciseDisposed | −50,437 | $0.00 | $0 | 353,066 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average share price of an aggregate total of 11,914 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average share price of an aggregate total of 15,833 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.